What is the share price of F D C Ltd (FDC) today?
The share price of FDC as on 29th May 2026 is ₹405. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.What is the return on F D C Ltd (FDC) share?
The past returns of F D C Ltd (FDC) share are- Past 1 week: 11.80%
- Past 1 month: 10.78%
- Past 3 months: 13.56%
- Past 6 months: -0.77%
- Past 1 year: -8.55%
- Past 3 years: 37.29%
- Past 5 years: 18.70%
What are the peers or stocks similar to F D C Ltd (FDC)?
The peers or stocks similar to F D C Ltd (FDC) include:What is the dividend yield % of F D C Ltd (FDC) share?
The current dividend yield of F D C Ltd (FDC) is 1.23.What is the market cap of F D C Ltd (FDC) share?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of F D C Ltd (FDC) is ₹6593.81 Cr as of 29th May 2026.What is the 52 week high and low of F D C Ltd (FDC) share?
The 52-week high of F D C Ltd (FDC) is ₹527.80 and the 52-week low is ₹312.95.What is the PE and PB ratio of F D C Ltd (FDC) stock?
The P/E (price-to-earnings) ratio of F D C Ltd (FDC) is 23.43. The P/B (price-to-book) ratio is 2.89.Which sector does F D C Ltd (FDC) belong to?
F D C Ltd (FDC) belongs to the Health Care sector & Pharmaceuticals sub-sector.How to buy F D C Ltd (FDC) shares?
You can directly buy F D C Ltd (FDC) shares on Tickertape. Simply sign up, connect your demat account and place your order.
F D C Ltd
FDC Share Price
NSE₹405.005.72% (-24.55)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
SIP
1D
1W
1M
1Y
5Y
Max
SIP
FDC Stock Scorecard
Performance
LowHasn't fared well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
FDC Performance & Key Metrics
FDC Performance & Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| 23.43 | 2.89 | 1.23% |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 40.72 | 6.24 | 0.47% |
FDC Analyst Ratings & Forecast
—
Analyst Ratings data is currently unavailable for this stockPrice Upside
Earnings Growth
Rev. Growth
FDC Company Profile
FDC Limited is a pharmaceutical company engaged in manufacture of specialized formulations, and oral rehydration salts (ORS). Its brands include Zifi, Electral, Enerzal, Vitcofol, Pyrimon, Zocon, Zoxan, Zathrin, Zipod, Zefu, Cotaryl and Mycoderm.
SUNPHARMA
PE Ratio
37.61
37.61
1Y Return
5.85%
5.85%
Buy Reco %
93.75
93.75
TORNTPHARM
PE Ratio
69.82
69.82
1Y Return
39.53%
39.53%
Buy Reco %
81.48
81.48
CIPLA
PE Ratio
29.17
29.17
1Y Return
5.14%
5.14%
Buy Reco %
62.86
62.86
DRREDDY
PE Ratio
25.87
25.87
1Y Return
4.43%
4.43%
Buy Reco %
51.52
51.52
ZYDUSLIFE
PE Ratio
21.52
21.52
1Y Return
16.54%
16.54%
Buy Reco %
53.57
53.57
FDC Forecast
FDC Forecasts
Forecast data is currently unavailable
Forecast data is currently unavailable
Price
Price Upside
Revenue
Revenue Growth
Earnings
Earnings Per Share
FDC
FDC
Income
Balance Sheet
Cash Flow
Quarterly Normal View
FDC Income Statement
FDC Income Statement
Quarterly Normal View
| Quarter | dec 2023 | mar 2024 | jun 2024 | sep 2024 | dec 2024 | mar 2025 | jun 2025 | sep 2025 | dec 2025 | mar 2026 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 482.87 | 482.30 | 666.71 | 548.55 | 482.94 | 507.97 | 683.91 | 493.66 | 485.51 | 634.68 | ||||||||||
Operating & Other expenses | 374.38 | 405.71 | 491.65 | 443.69 | 417.46 | 437.91 | 508.06 | 439.22 | 433.22 | 478.43 | ||||||||||
EBITDA | 108.49 | 76.59 | 175.06 | 104.86 | 65.48 | 70.06 | 175.85 | 54.44 | 52.29 | 156.25 | ||||||||||
| Depreciation/Amortization | 9.97 | 10.44 | 11.02 | 13.79 | 13.36 | 15.56 | 14.91 | 15.20 | 14.78 | 14.35 | ||||||||||
| PBIT | 98.52 | 66.15 | 164.04 | 91.07 | 52.12 | 54.50 | 160.94 | 39.24 | 37.51 | 141.90 | ||||||||||
| Interest & Other Items | 0.97 | 0.95 | 1.30 | 1.07 | 0.95 | 1.19 | 1.17 | 1.15 | 1.12 | 1.55 | ||||||||||
| PBT | 97.55 | 65.20 | 162.74 | 90.00 | 51.17 | 53.31 | 159.77 | 38.09 | 36.39 | 140.35 | ||||||||||
| Taxes & Other Items | 18.31 | 18.92 | 43.70 | 17.96 | 14.14 | 14.63 | 38.42 | 9.72 | 8.08 | 36.96 | ||||||||||
| Net Income | 79.24 | 46.28 | 119.04 | 72.04 | 37.03 | 38.68 | 121.35 | 28.37 | 28.31 | 103.39 | ||||||||||
| EPS | 4.86 | 2.84 | 7.31 | 4.43 | 2.28 | 2.38 | 7.45 | 1.75 | 1.74 | 6.35 |
FDC Company Updates
FDC Stock Peers
FDC Past Performance & Peer Comparison
FDC Past Performance & Peer Comparison
Comparing 3 stocks from
Health CarePharmaceuticals
Compare valuation on Screener
Health CarePharmaceuticals
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| F D C Ltd | 23.43 | 2.89 | 1.23% |
| Sun Pharmaceutical Industries Ltd | 37.61 | 5.96 | 0.89% |
| Torrent Pharmaceuticals Ltd | 69.82 | 19.67 | — |
| Cipla Ltd | 29.17 | 3.62 | 0.93% |
FDC Stock Price Comparison
Compare FDC with any stock or ETFCompare FDC with any stock or ETF
FDC
FDC Holdings
FDC Shareholdings
FDC Promoter Holdings Trend
FDC Promoter Holdings Trend
Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better
Pledged promoter holdings is insignificant
FDC Institutional Holdings Trend
FDC Institutional Holdings Trend
Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock
In last 3 months, foreign institutional holding of the company has almost stayed constant
FDC Shareholding Pattern
FDC Shareholding Pattern
FDC Shareholding History
FDC Shareholding History
Foreign Institutions
Mutual Funds Invested in FDC
Mutual Funds Invested in FDC
No mutual funds holding trends are available
Top 5 Mutual Funds holding F D C Ltd
| Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
|---|---|---|---|---|
The rupee value of the stock held by the fund divided by the stock’s market cap 2.3630% | Percentage of the fund’s portfolio invested in the stock 0.21% | Change in the portfolio weight of the stock over the last 3 months -0.01% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 113/262 (+86) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 1.1165% | Percentage of the fund’s portfolio invested in the stock 0.84% | Change in the portfolio weight of the stock over the last 3 months -0.02% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 24/153 (+3) | |
The rupee value of the stock held by the fund divided by the stock’s market cap 0.6693% | Percentage of the fund’s portfolio invested in the stock 0.66% | Change in the portfolio weight of the stock over the last 3 months 0.03% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 35/44 (0) |
Compare 3-month MF holding change on Screener
Hmm, looks like there hasn't been any net deal activity in the last 6 monthssmallcases containing FDC stock
smallcases containing FDC stock
Looks like this stock is not in any smallcase yet.
FDC Events
FDC Events
FDC Dividend Trend
No dividend trend available
Dividends
Corp. Actions
Announcements
Legal Orders
Dividends
FDC Dividend Trend
No dividend trend available
FDC Upcoming Dividends
FDC Upcoming Dividends
No upcoming dividends are available
FDC Past Dividends
FDC Past Dividends
Cash Dividend
Ex DateEx DateFeb 11, 2026
Interim 1
Interim 1 | Div/Share: ₹5.00
Dividend/Share
₹5.00
Ex DateEx Date
Feb 11, 2026
Cash Dividend
Ex DateEx DateNov 22, 2024
Interim 1
Interim 1 | Div/Share: ₹5.00
Dividend/Share
₹5.00
Ex DateEx Date
Nov 22, 2024
Cash Dividend
Ex DateEx DateMar 19, 2020
Interim
Interim | Div/Share: ₹0.80
Dividend/Share
₹0.80
Ex DateEx Date
Mar 19, 2020
Cash Dividend
Ex DateEx DateAug 8, 2017
Final
Final | Div/Share: ₹2.25
Dividend/Share
₹2.25
Ex DateEx Date
Aug 8, 2017
Cash Dividend
Ex DateEx DateMar 17, 2016
Interim
Interim | Div/Share: ₹2.25
Dividend/Share
₹2.25
Ex DateEx Date
Mar 17, 2016
FDC Stock News & Opinions
FDC Stock News & Opinions
Articles & Videos
Earnings
Earnings
FDC consolidated net profit rises 167.39% in the March 2026 quarterNet profit of FDC rose 167.39% to Rs 103.40 crore in the quarter ended March 2026 as against Rs 38.67 crore during the previous quarter ended March 2025. Sales rose 18.89% to Rs 584.79 crore in the quarter ended March 2026 as against Rs 491.89 crore during the previous quarter ended March 2025. For the full year,net profit rose 5.48% to Rs 281.42 crore in the year ended March 2026 as against Rs 266.79 crore during the previous year ended March 2025. Sales rose 2.98% to Rs 2170.93 crore in the year ended March 2026 as against Rs 2108.12 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales584.79491.89 19 2170.932108.12 3 OPM %18.1910.97 -15.9415.41 - PBDT154.7068.87 125 454.63410.95 11 PBT140.3553.31 163 395.39357.22 11 NP103.4038.67 167 281.42266.79 5 Powered by Capital Market - Live
3 days agoCapital Market - Live
Earnings
Earnings
FDC standalone net profit rises 122.04% in the March 2026 quarterNet profit of FDC rose 122.04% to Rs 107.07 crore in the quarter ended March 2026 as against Rs 48.22 crore during the previous quarter ended March 2025. Sales rose 17.09% to Rs 564.36 crore in the quarter ended March 2026 as against Rs 482.00 crore during the previous quarter ended March 2025. For the full year,net profit rose 4.49% to Rs 285.92 crore in the year ended March 2026 as against Rs 273.63 crore during the previous year ended March 2025. Sales rose 2.72% to Rs 2126.33 crore in the year ended March 2026 as against Rs 2070.11 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales564.36482.00 17 2126.332070.11 3 OPM %19.7810.96 -16.5615.47 - PBDT157.2783.08 89 458.25421.29 9 PBT142.9667.55 112 399.15367.68 9 NP107.0748.22 122 285.92273.63 4 Powered by Capital Market - Live
3 days agoCapital Market - Live
Corporate
Corporate
FDC to announce Quarterly ResultFDC will hold a meeting of the Board of Directors of the Company on 27 May 2026.
1 week agoCapital Market - Live
Corporate
Corporate
FDC receives USFDA approval for Cefixime for Oral SuspensionFDC has granted ANDA approval by United States Food and Drug Administration (U.S.FDA), for Cefixime for Oral Suspension USP, 100 mg / 5 mL and 200 mg/ 5 mL.
1 week agoCapital Market - Live
Earnings
Earnings
FDC consolidated net profit declines 23.60% in the December 2025 quarterNet profit of FDC declined 23.60% to Rs 28.30 crore in the quarter ended December 2025 as against Rs 37.04 crore during the previous quarter ended December 2024. Sales rose 0.13% to Rs 464.71 crore in the quarter ended December 2025 as against Rs 464.11 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales464.71464.11 0 OPM %11.2510.05 - PBDT71.9664.53 12 PBT57.1751.18 12 NP28.3037.04 -24 Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Corporate
Board of FDC recommends First Interim DividendFDC announced that the Board of Directors of the Company at its meeting held on 05 February 2026, has recommended a First Interim Dividend of Rs.5 per share (i.e.500%), subject to the approval of the shareholders.Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Corporate
FDC to conduct board meetingFDC will hold a meeting of the Board of Directors of the Company on 5 February 2026.Powered by Capital Market - Live
3 months agoCapital Market - Live
Corporate
Corporate
FDC receives USFDA approval for Fluconazole TabletsFDC has been granted ANDA approval by United States Food and Drug Administration (U.S.FDA), for Fluconazole Tablets USP, 50 mg, 100 mg, 150 mg and 200 mg.Powered by Capital Market - Live
4 months agoCapital Market - Live
Earnings
Earnings
FDC consolidated net profit declines 60.62% in the September 2025 quarterNet profit of FDC declined 60.62% to Rs 28.37 crore in the quarter ended September 2025 as against Rs 72.04 crore during the previous quarter ended September 2024. Sales declined 7.94% to Rs 473.03 crore in the quarter ended September 2025 as against Rs 513.85 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales473.03513.85 -8 OPM %7.1513.65 - PBDT53.29103.79 -49 PBT38.0990.00 -58 NP28.3772.04 -61 Powered by Capital Market - Live
6 months agoCapital Market - Live
Corporate
Corporate
FDC to declare Quarterly ResultsFDC will hold a meeting of the Board of Directors of the Company on 5 November 2025.Powered by Capital Market - Live
7 months agoCapital Market - Live
Over the last 5 years, revenue has grown at a yearly rate of 9.25%, vs industry avg of 9.86%
Over the last 5 years, market share decreased from 0.56% to 0.52%
Over the last 5 years, net income has grown at a yearly rate of 2.15%, vs industry avg of 19.71%